Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties

Trubetskoy, Vladimir S.; Cannillo, John; Milshtein, Alexander; Wolf, Gerald; Torchilin, Vladimir P.

doi:10.1016/0730-725x(94)00083-f

Cited by 95 publications

(40 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The applicability of such liposomal contrast agents is broad. Pegylated liposomes have been used as a blood pool agent (136), for the detection of lymph nodes (136) and to achieve sustained contrast enhancement of tumors (137). Regions of enhanced permeability can be detected upon injection of paramagnetic liposomes, which is useful e.g.…”

Section: Lipid-based Mri Contrast Agents: Applications Liposomal Contmentioning

confidence: 99%

Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging

et al. 2006

View full text Add to dashboard Cite

In the field of MR imaging and especially in the emerging field of cellular and molecular MR imaging, flexible strategies to synthesize contrast agents that can be manipulated in terms of size and composition and that can be easily conjugated with targeting ligands are required. Furthermore, the relaxivity of the contrast agents, especially for molecular imaging applications, should be very high to deal with the low sensitivity of MRI. Lipid-based nanoparticles, such as liposomes or micelles, have been used extensively in recent decades as drug carrier vehicles. A relatively new and promising application of lipidic nanoparticles is their use as multimodal MR contrast agents. Lipids are amphiphilic molecules with both a hydrophobic and a hydrophilic part, which spontaneously assemble into aggregates in an aqueous environment. In these aggregates, the amphiphiles are arranged such that the hydrophobic parts cluster together and the hydrophilic parts face the water. In the low concentration regime, a wide variety of structures can be formed, ranging from spherical micelles to disks or liposomes. Furthermore, a monolayer of lipids can serve as a shell to enclose a hydrophobic core. Hydrophobic iron oxide particles, quantum dots or perfluorocarbon emulsions can be solubilized using this approach. MR-detectable and fluorescent amphiphilic molecules can easily be incorporated in lipidic nanoparticles. Furthermore, targeting ligands can be conjugated to lipidic particles by incorporating lipids with a functional moiety to allow a specific interaction with molecular markers and to achieve accumulation of the particles at disease sites. In this review, an overview of different lipidic nanoparticles for use in MRI is given, with the main emphasis on Gd-based contrast agents. The mechanisms of particle formation, conjugation strategies and applications in the field of contrast-enhanced, cellular and molecular MRI are discussed.

show abstract

Section: Lipid-based Mri Contrast Agents: Applications Liposomal Contmentioning

confidence: 99%

Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging

et al. 2006

View full text Add to dashboard Cite

show abstract

“…tumors or atherosclerotic plaques) or containing high amount of macrophages (liver, spleen), (iv) easiness to prepare vesicles able to recognize a specific biological target. Liposomes loaded with paramagnetic Mn(II)-or Gd(III)-based imaging reporters or superparamagnetic iron oxide particles have been investigated for many applications including passive and active tumor visualization [3][4][5][6][7], detection of myocardium infarcted areas [8], imaging of lymph nodes [9], visualization of atherosclerotic plaques [10], detection of multiple sclerosis [11], bone marrow visualization [12], detection of apoptosis [13], in vivo monitoring of temperature [14] or pH [15], and imaging of drug delivery [16,17]. In addition, liposomes loaded with paramagnetic lanthanide(III) complexes, mostly different from Gd(III), have been recently proposed as highly sensitive MRI agents acting as chemical exchange saturation transfer (CEST) probes [18][19][20][21] or as T 2 susceptibility agents [22].…”

Section: Introductionmentioning

confidence: 99%

Determination of water permeability of paramagnetic liposomes of interest in MRI field

Terreno

Sanino

Carrera

et al. 2008

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

“…Encapsulation or membrane binding of imaging agents to liposomes has been shown to reduce the risk of leakage of potentially toxic metals into the bloodstream or other body compartments [ 30 ]. Liposomes loaded with paramagnetic ions (e.g., Gd, Mn, Fe) have proven successful in the visualization of the lymphatic system [ 31 ], which may have application in detecting lymph node metastases [ 31 , 32 ]. 111 In-labeled PEGylated liposomes ( 111 In-DTPA-PEGylated liposomes) have demonstrated distinctive characteristics in the visualization of lung [ 33 , 34 ], head, and neck cancers [ 33 , 34 ], glioblastomas [ 35 ], as well as other malignant tumors [ 33 ].…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Nanotechnology in Cancer

Janát-Amsbury

Bae

2013

Cancer Drug Discovery and Development

View full text Add to dashboard Cite

Cancer nanotechnology, defi n ed as nanotechnology applicable for diagnosis, prognosis, and therapy of cancer, offers exciting possibilities but also challenges. Although nanotechnology became fruitful in the fi eld of diagnostics, to date the desire of improving current cancer treatments through nanotechnology has surpassed the research or development stage only in a handful of cases. However, efforts to clinically translate more of these treatments remain highly focused. Drug-bearing nanoparticles, which are usually injected directly into the bloodstream, are sent on a journey full of obstacles to overcome such as bypassing RES organs and crossing endothelial cells, as well as various membranes of cellular and extracellular compartments, before fi nally encountering tumor tissue. Therefore, a cornucopia of different nanoparticle designs varying in size, architecture, and surface properties has been designed to be deployed to tumor sites within the human body either passively or promoting the association with a particular cell or tissue type through targeting. Early clinical results with nanomedicines were indeed able to show reduced toxicity, improving patients' quality of life, but are still in need of stronger coupling with superior clinical effi cacy to help justify the often high costs associated with this new class of therapeutics and their complexity. Nanotechnology aiming for the development of novel cancer therapeutics must focus in on potential, unforeseen toxicities and also consider the emerging role of epigenetics. The following chapter introduces most of the basic nanoconstructs developed to date, which inevitably will continue to evolve and eventually fi nd an important place in health care, though to become the cancer medicines of tomorrow, nanotechnology's future success and translation must early on be connected to diagnostic and therapeutic potential for clinical applications. To be equally aware of potential benefi ts, risks and costs will be necessary to stimulate future research with emphases on how to improve therapeutic outcomes such as the extension of life in patients with cancer in times burdened with unsustainable healthcare costs.

show abstract

Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties

Cited by 95 publications

References 12 publications

Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging

Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging

Determination of water permeability of paramagnetic liposomes of interest in MRI field

Nanotechnology in Cancer

Contact Info

Product

Resources

About